Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.

By A. Goldhirsch, W. Wood, R. Gelber, A. Coates, B. Thürlimann, H. Senn. Journal of Clinical Oncology, 2003

745 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e54af05af26f793482c844f577e2bb9584fe0c74

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Pulmonary and Respiratory Medicine

K. Pantel

Citations in the corpus

Prevalence of and factors associated with persistent pain following breast cancer surgery. (2009, neutral): “Severe 34 (10) 23 (13) 17 (16) 8 (13) 12 (8) 29 (17) 1 (3) 4 (13) 10 (16) 6 (12) 35 (20) 22 (14) 201 (13)”
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients (2007, background): “Clinical trials have also shown that the survival advantage for women with hormone receptor-positive tumors is enhanced by treatment with adjuvant hormonal and/or chemotherapeutic regimens [7-9].”
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “Indications for radiation therapy after mastectomy are unchanged from previous St Gallen Meeting highlights [1], although computed tomography scan-based simulation, especially for left-sided cancers, may ensure that the heart is not included in the radiation fields [1, 147, 148].”
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients (2007, background): “…still not considered as an established factor to be used in clinical practice, probably because most of the studies are retrospective and because some uncertainty remains on the way Ki-67 should be assessed (Eifel et al, 2001; Goldhirsch et al, 2003; Colozza et al, 2005; Urruticoechea et al, 2005).”
Dissecting the metastatic cascade (2004, background): “For example, only 20–25% of patients with breast cancer without overt lymph-node metastases undergo metastatic relapse within 10 years post-surgery, but more than 90% of these patients are supposed to receive chemotherapy according to the new consensus recommendation”
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. (2008, neutral): “chemoprevention and intensified surveillance” (350).”